Welcome to our dedicated page for Autonomix Medical news (Ticker: AMIX), a resource for investors and traders seeking the latest updates and insights on Autonomix Medical stock.
Autonomix Medical Inc (AMIX) is a pioneer in developing catheter-based neural sensing technologies for neurological disorders. This page provides centralized access to official company announcements, regulatory updates, and breakthrough developments in microchip-enabled medical diagnostics.
Investors and industry professionals will find timely updates on AMIX's R&D milestones, strategic partnerships, and preclinical progress with its proprietary neural signal detection platform. The curated news feed ensures accurate tracking of advancements in minimally invasive neural disorder treatments.
Key updates include regulatory submissions, research collaborations, technology validations, and intellectual property developments. All content is sourced directly from company filings and authorized communications to maintain compliance and reliability.
Bookmark this page for streamlined monitoring of AMIX's progress in redefining neurological diagnostics through its microchip-integrated catheter technology. Check back regularly for verified updates on this development-stage innovator's journey toward clinical impact.
Autonomix Medical (NASDAQ: AMIX) has completed the final design review of its groundbreaking intravascular nerve sensing catheter, marking a significant milestone toward U.S. clinical trials. The device, featuring a proprietary microchip-based sensing antenna array, is the first of its kind capable of detecting and differentiating nerve signals in real-time from within blood vessels.
The technology enables a novel "sense, treat and verify" approach, allowing physicians to detect nerve activity, guide energy delivery precisely, and confirm treatment efficacy during procedures. The company is preparing to submit an Investigational Device Exemption (IDE) to commence clinical trials, initially focusing on treating pancreatic cancer pain, with potential applications across multiple therapeutic areas including cardiology, pain management, and pulmonary disorders.
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment technologies, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
During the conference, CEO Brad Hauser shared insights about his career journey, his commitment to Autonomix, and his enthusiasm for the company's innovative technology. The presentation is now available for viewing on both the Virtual Investor website and the Events page in the Investors section of autonomix.com.
Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has secured $2.5 million in gross proceeds through warrant exercises. The company entered agreements with certain warrant holders to exercise warrants for 1,477,596 shares at a reduced price of $1.723 per share.
In exchange for the immediate exercise, Autonomix will issue new unregistered warrants for an equivalent number of shares, exercisable at $1.723 per share with a five-and-a-half-year term. Some holders opted to prepay $1.722 of the exercise price, receiving amended warrants with a $0.001 exercise price. The transaction is expected to close around July 23, 2025.
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,295,646 for its "Smart Torquer" device, strengthening its intellectual property portfolio in nerve-sensing and modulation technology. The patent covers a device designed to enhance the manipulation of intravascular devices during minimally invasive procedures while enabling data communication.
The company's technology platform features a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with enhanced sensitivity, followed by proprietary RF ablation for targeted nerve treatment. With over 80 issued patents and 40 pending applications, Autonomix is positioning itself in a multi-billion-dollar market opportunity across cardiovascular, renal, and other high-burden diseases.
Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has released a new CEO Corner segment featuring CEO Brad Hauser. The segment, now available on the company's website, discusses details about the company's recently announced planned follow-on market expansion study phase (PoC 2) of its proof-of-concept trial.
Autonomix Medical (NASDAQ:AMIX) has announced the enrollment and treatment of its first patient in the follow-on phase of its proof-of-concept human clinical trial (PoC 2). This expansion follows positive results from the initial PoC 1 study in patients with severe pancreatic cancer pain.
The PoC 2 phase aims to double the potential addressable market by evaluating the company's nerve ablation technology in additional visceral cancers that signal pain through the Celiac Plexus, as well as earlier stage pancreatic cancers with moderate to severe pain. The technology involves delivering transvascular energy to ablate problematic nerves for pain mitigation.
The company's platform technology has potential applications across multiple indications, including cardiology, hypertension, and chronic pain management. The current PoC 2 phase specifically focuses on interventional cancer pain management applications in areas such as pancreatic, gall bladder, liver, and bile duct cancers, with possibilities for further expansion in oncology and gastroenterology sectors.
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,279,889 B2 for its innovative catheter-based platform technology. The patent covers advanced systems for locating, monitoring, and mapping electrophysiological signals during neuromodulation procedures.
The technology features a catheter-based microchip sensing array antenna designed to detect neural signals with enhanced sensitivity, followed by proprietary RF ablation for targeted nerve treatment. Key applications include chronic pain management, hypertension treatment, and cardiac modulation. The company plans to submit an IDE and begin U.S. clinical trials in 2025 for pancreatic cancer pain treatment.
Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,257,071 for its innovative catheter-based platform technology. The patent covers advanced systems combining nerve mapping and radiofrequency (RF) ablation technologies for treating nerve-related conditions. Key features include deployable microfingers with embedded sensors, real-time physiological monitoring, and adaptive modulation capabilities.
The technology utilizes a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with enhanced sensitivity compared to existing solutions. The company's portfolio now includes over 80 issued patents and 40 pending applications. Autonomix plans to submit an Investigational Device Exemption (IDE) and begin U.S. clinical trials in 2025 for treating pancreatic cancer pain.
Autonomix Medical (NASDAQ: AMIX) announced its participation in the Virtual Investor Closing Bell Series scheduled for May 22, 2025, at 4:00 PM ET. During the event, CEO Brad Hauser will provide a corporate overview and discuss the company's innovative catheter-based microchip sensing array technology. This first-in-class platform system aims to enhance neural signal detection and differentiation compared to existing technologies.
The event will include a live interactive Q&A session where investors can submit questions. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days following the event.
FAQ
What is the current stock price of Autonomix Medical (AMIX)?
What is the market cap of Autonomix Medical (AMIX)?
